Drug Profile
DAB389interleukin-4
Alternative Names: Interleukin-4 diphtheria toxin chimeric protein; Interleukin-4 fusion toxinLatest Information Update: 14 Feb 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; Seragen
- Class Interleukins
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Graft-versus-host disease; Hypersensitivity; Leukaemia; Lymphoma
Most Recent Events
- 14 Feb 2001 Discontinued-Preclinical for Allergy in USA (Unknown route)
- 14 Feb 2001 Discontinued-Preclinical for Autoimmune disorders in USA (Unknown route)
- 14 Feb 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)